| 1 |
Biosimilars as a Future, Promising Solution for Financial Toxicity: A Review with Emphasis on Bevacizumab |
|
|
| Tabinda Saleem,Hafiz Qurashi,Munira Jamali,Janet Chan Gomez,Tejaswi Kanderi |
|
| Cureus. 2020; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
Close, but no cigar: Biosimilar products and firm regulatory stance |
|
|
| Julie Babyar |
|
| International Journal of Healthcare Management. 2020; : 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Streptokinase: An Efficient Enzyme in Cardiac Medicine |
|
|
| Muhammad A. Zia |
|
| Protein & Peptide Letters. 2020; 27(2): 111 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis—a real-life experience |
|
|
| Sakshi Mittal,G. S. R. S. N. K. Naidu,Saket Jha,Manish Rathi,Ritambhra Nada,Ranjana W Minz,Kusum Sharma,Varun Dhir,Sanjay Jain,Aman Sharma |
|
| Clinical Rheumatology. 2020; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Highly mucus permeating and zeta potential changing self-emulsifying drug delivery systems: A potent gene delivery model for causal treatment of cystic fibrosis |
|
|
| Janine Griesser,Gergely Hetényi,Christoph Federer,Christian Steinbring,Helmut Ellemunter,Katharina Niedermayr,Andreas Bernkop-Schnürch |
|
| International Journal of Pharmaceutics. 2019; 557: 124 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
Rituximab biosimilar CT-P10 for the treatment of rheumatoid arthritis |
|
|
| Ju-Yang Jung,Ji-Won Kim,Hyoun-Ah Kim,Chang-Hee Suh |
|
| Expert Opinion on Biological Therapy. 2019; : 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 7 |
Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region |
|
|
| Prasan Deep Rath,Der-Yuan Chen,Jieruo Gu,Vivian W. Y. Lee,Nizar Abdulateef Al Ani,Khalid Shirazy,Lyndon Llamado |
|
| International Journal of Rheumatic Diseases. 2018; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 8 |
Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis |
|
|
| Imran H. Iftikhar,Mathew Schimmel,William Bender,Colin Swenson,David Amrol |
|
| Lung. 2018; 196(5): 517 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 9 |
Biocompatible Polymers Modified with d-Octaarginine as an Absorption Enhancer for Nasal Peptide Delivery |
|
|
| Kohei Miyata,Masami Ukawa,Kohta Mohri,Kozue Fujii,Mako Yamada,Sohei Tanishita,Satoshi Higashitarumi,Seiya Ishizaki,Hironori Kumagai,Kyohei Ochiai,Ken-ichiro Hiwatari,Kazufumi Tsubaki,Koichi Shigeno,Etsuo Tobita,Hideo Kobayashi,Shinji Sakuma |
|
| Bioconjugate Chemistry. 2018; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 10 |
Protein biomarkers for subtyping breast cancer and implications for future research |
|
|
| Claudius Mueller,Amanda Haymond,Justin B. Davis,Alexa Williams,Virginia Espina |
|
| Expert Review of Proteomics. 2018; : 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 11 |
The road from development to approval: evaluating the body of evidence to confirm biosimilarity |
|
|
| Paul Declerck,Mourad Farouk Rezk |
|
| Rheumatology. 2017; 56(suppl_4): iv4 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 12 |
Large Molecule Pharmacotherapy |
|
|
| Patricia Anne O’Malley |
|
| Clinical Nurse Specialist. 2017; 31(3): 134 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 13 |
Parallel experimental design and multivariate analysis provides efficient screening of cell culture media supplements to improve biosimilar product quality |
|
|
| David Brühlmann,Michael Sokolov,Alessandro Butté,Markus Sauer,Jürgen Hemberger,Jonathan Souquet,Hervé Broly,Martin Jordan |
|
| Biotechnology and Bioengineering. 2017; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 14 |
Improving Access to Cancer Treatments: The Role of Biosimilars |
|
|
| Rakesh Chopra,Gilberto Lopes |
|
| Journal of Global Oncology. 2017; 3(5): 596 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 15 |
Personalized medicine with biologics for severe type 2 asthma: current status and future prospects |
|
|
| Marie Godar,Christophe Blanchetot,Hans de Haard,Bart N. Lambrecht,Guy Brusselle |
|
| mAbs. 2017; : 00 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 16 |
Biosimilars in Germany: the emergence of a new industry in the light of the varieties of capitalism approach |
|
|
| Andreas Pyka,Tobias Buchmann,Ben Vermeulen |
|
| Technology Analysis & Strategic Management. 2016; : 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 17 |
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations |
|
|
| Sara Francescon,Giulia Fornasier,Paolo Baldo |
|
| Oncology and Therapy. 2016; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 18 |
Key strategic factors for stakeholders in the current global biosimilar market |
|
|
| Daniel Casey |
|
| Drug Discovery Today. 2016; 21(2): 208 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 19 |
Recent Advances in Application of Pharmacogenomics for Biotherapeutics |
|
|
| Pramod B. Mahajan |
|
| The AAPS Journal. 2016; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 20 |
Using simple models to describe the kinetics of growth, glucose consumption, and monoclonal antibody formation in naive and infliximab producer CHO cells |
|
|
| Julián López-Meza,Diana Araíz-Hernández,Leydi Maribel Carrillo-Cocom,Felipe López-Pacheco,María del Refugio Rocha-Pizaña,Mario Moisés Alvarez |
|
| Cytotechnology. 2015; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 21 |
Fractal geometry as a new approach for proving nanosimilarity: A reflection note |
|
|
| Costas Demetzos,Natassa Pippa |
|
| International Journal of Pharmaceutics. 2015; 483(1-2): 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
